» Articles » PMID: 35563522

MicroRNA-449a Inhibits Triple Negative Breast Cancer by Disturbing DNA Repair and Chromatid Separation

Abstract

Chromosomal instability (CIN) can be a driver of tumorigenesis but is also a promising therapeutic target for cancer associated with poor prognosis such as triple negative breast cancer (TNBC). The treatment of TNBC cells with defects in DNA repair genes with poly(ADP-ribose) polymerase inhibitor (PARPi) massively increases CIN, resulting in apoptosis. Here, we identified a previously unknown role of microRNA-449a in CIN. The transfection of TNBC cell lines HCC38, HCC1937 and HCC1395 with microRNA-449a mimics led to induced apoptosis, reduced cell proliferation, and reduced expression of genes in homology directed repair (HDR) in microarray analyses. was identified as a new target gene by immunoprecipitation and luciferase assays. The reduced expression of led to an increased frequency of ultrafine bridges, 53BP1 foci, and micronuclei. The induced expression of microRNA-449a elevated CIN beyond tolerable levels and induced apoptosis in TNBC cell lines by two different mechanisms: (I) promoting chromatid mis-segregation by targeting endonuclease and (II) inhibiting HDR by downregulating key players of the HDR network such as , , and . The ectopic expression of microRNA-449a enhanced the toxic effect of PARPi in cells with pathogenic germline variants. The newly identified role makes microRNA-449a an interesting therapeutic target for TNBC.

Citing Articles

m6A methylation profiling as a prognostic marker in nasopharyngeal carcinoma: insights from MeRIP-Seq and RNA-Seq.

Chen X, Xu W, Pan J, Yang H, Li Y, Chen X Front Immunol. 2024; 15:1492648.

PMID: 39726587 PMC: 11669702. DOI: 10.3389/fimmu.2024.1492648.


MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer.

Torres-Ruiz S, Garrido-Cano I, Lameirinhas A, Burgues O, Hernando C, Martinez M Cell Death Discov. 2024; 10(1):372.

PMID: 39174500 PMC: 11341569. DOI: 10.1038/s41420-024-02128-7.


Molecular targets and therapeutic strategies for triple-negative breast cancer.

Bhat Y, Thrishna M, Banerjee S Mol Biol Rep. 2023; 50(12):10535-10577.

PMID: 37924450 DOI: 10.1007/s11033-023-08868-6.

References
1.
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

2.
Tutt A, Robson M, Garber J, Domchek S, Audeh M, Weitzel J . Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010; 376(9737):235-44. DOI: 10.1016/S0140-6736(10)60892-6. View

3.
Fang Y, Gu X, Li Z, Xiang J, Chen Z . miR-449b inhibits the proliferation of SW1116 colon cancer stem cells through downregulation of CCND1 and E2F3 expression. Oncol Rep. 2013; 30(1):399-406. DOI: 10.3892/or.2013.2465. View

4.
Stevens K, Vachon C, Couch F . Genetic susceptibility to triple-negative breast cancer. Cancer Res. 2013; 73(7):2025-30. PMC: 3654815. DOI: 10.1158/0008-5472.CAN-12-1699. View

5.
Geng D, Song X, Ning F, Song Q, Yin H . MiR-34a Inhibits Viability and Invasion of Human Papillomavirus-Positive Cervical Cancer Cells by Targeting E2F3 and Regulating Survivin. Int J Gynecol Cancer. 2015; 25(4):707-13. DOI: 10.1097/IGC.0000000000000399. View